According to the World Health Organization (WHO), breast cancer is the second most common cancer in the world and the most common cancer in women worldwide, accounting for 25% of all incident cases of female cancers. It is estimated that 2.3 million women were diagnosed with breast cancer and 700,000 deaths caused by breast cancer globally in 2020.
As with all cancers, early detection and treatment of breast cancer are associated with better outcomes and reduced mortality. That’s why knowing the signs and symptoms and regularly checking your breasts are important.
Generally, breast cancer presents as a painless lump or thickening of the breast tissue. Although there are many reasons for a lump to develop in breast tissue, many non-cancerous, any abnormal lump should be checked out by a doctor as soon as possible. It’s always better to get checked.
Other signs include:
Breast cancer treatment can be highly effective, particularly when the disease is detected early. Treatments include surgery, radiotherapy, and anti-cancer medicines including endocrine (hormone) therapy, chemotherapy and in some cases targeted biologic therapy (antibodies).
Significant progress has been made in recent years in the treatment of breast cancer which has helped reduce mortality. In high income countries including North America and Western European countries, which lead the world in breast cancer incidence (well over 60 and up to 95 per 100,000 women ages 0-69), breast cancer mortality rates have shrunk to less than 15%. However, these gains have not been universal and in lower income countries in Eastern Europe, Asia, Africa, and South America, even with significantly lower incidence rates (as low as 15-20 patients per 100,000), the mortality rates remain as high as 50% or more, and represent 58% of global mortality.
At Cromos Pharma our first clinical research project was conducted in breast cancer. Since 2004, we have conducted dozens of trials involving thousands of breast cancer patients. These studies have focused on a range of areas from finding innovative targeted therapies to biosimilar and generic studies aimed at offering wider access to novel treatments. In 2019, our team successfully recruited almost 500 patients (92% of total) for a multi-country breast cancer study in just seven months.
Cromos Pharma’s breast cancer research projects have been aimed at introducing treatment modalities from high income countries to thousands of patients who live in the low income regions of the world. They have been designed to introduce new medicines as well as less expensive but proven follow-on generic and biosimilar medications to regions where healthcare reimbursement is not available for novel or costly therapies. They have enabled physicians to provide education, early diagnosis, and advanced, targeted therapies to their patients. We are proud that we have played our part in increasing access to treatments.
Cromos Pharma is a US-based international contract research organization with 16 years' experience in delivering fully integrated clinical research solutions in all aspects of clinical trials in all clinical phases across a wide range of therapeutic areas. Our expert team boasts wide-ranging expertise in study design, medical writing, regulatory affairs, site management, patient recruitment and data management.
From bioequivalence studies, biosimilars and generics to successfully managing oncology, neurology, dermatology clinical trials our team provides full service solutions to international pharma and biotech in high recruiting regions with high quality data assured.
Established in 2004, Cromos Pharma has strong regional experience in Central and Eastern Europe supported by an extensive network of offices. Its international HQ is in Portland, Oregon, USA.
We combine global expertise with in-depth experience and knowledge in Central and Eastern Europe to offer exceptional patient recruitment. In our 16 year history, our team has met or reduced enrollment timelines in 95% of trials conducted. Responsible recruitment is supported by our “No Patients-No Payments” initiative – a unique risk-sharing program.
We provide the most optimized start-up timelines in our regions. We regularly achieve regulatory approvals in Georgia, within two months of project signing (4 months in Russia, and in less than 5 in Ukraine). Regulatory inspections and site audits also attest to the highest quality of our clinical data: EMA in 2019 (1-week oncology site inspection); FDA in 2017 (2-week oncology site inspection).
Cromos Pharma is delighted to be taking part in the upcoming DIA Europe conference (15 – 19 March 2021) and BIO-Europe Spring (22-25 March 2021).
February 11th is International Women and Girls in Science Day. A joint UNESCO and UN-Women initiative, it aims to promote the role of #WomenInScience and to challenge some of the barriers to girls pursuing a career in science.
Are you a sponsor seeking to conduct clinical trials in the European Union but do not have a registered office in the European Economic Area? If so, in order to comply with the European Union Clinical Trial Directive, you are required to work with a Legal Representative registered in an EEA country.
Each 4th February, #WorldCancerDay aims to raise awareness of the global personal, social and economic burden of cancer. World Cancer Day was established in Paris at the first World Cancer Summit in 2000.
As 2021 begins, many countries are grappling with a renewed surge of COVID-19 infections necessitating further public health restrictions putting more pressure on health systems, societies and global economies. The task of rolling out approved vaccines is increasingly urgent. Almost 16 million doses of COVID-19 vaccines have been administered to date in 37 countries worldwide according to data compiled by Bloomberg ( updated 7 Jan 2021).
Tuesday 1 December marked World AIDS Day 2020. Although throughout this year our focus has been on the coronavirus pandemic, World AIDS Day is an opportunity to reflect on another pandemic where a virus passed from animals to humans with devastating consequences. To date 77 million people worldwide have been infected with HIV. In spite of innovative new treatments 35 million people have died from the virus.
If you missed the live webinar “Where in the world should I locate my pivotal clinical trial?” you can now watch the recording by clicking here. The webinar hosted by the Society of Physician Entrepreneurs (SoPE) and Workforce Genetics features Cromos Pharma's CEO Vlad Bogin, M.D, FACP.